The P-III (ECHELON-1) trial evaluates Adcetris + AVD vs ABVD in 1,334 patients with prior untreated stage III or IV classical Hodgkin lymphoma
The results showed an improvement in OS at a median follow up of 73mos., 41% reduction in risk of death with an estimated OS rate (93.9% vs 89.4%) & PFS rate (82.3% vs 74.5%) @6yr., treatment-emergent peripheral neuropathy (86% vs 87%), completely resolving (72% vs 79%), and improving (14% vs 8%) by the last follow-up. The safety profile was consistent with prior studies with no new safety signals
Seagen has US & Canadian commercialization rights & Takeda will lead the development costs & got the rights to commercialize Adcetris globally. The companies share the equal cost for Adcetris on a 50:50 basis (Ex-Japan)
Ref: Seagen | Image: Seagen
